ELECTRO SENSORS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ELECTRO SENSORS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $7.84M | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | $7.17M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $7.64M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $7.04M | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | $6.54M | Mar 18, 2015 |
| FY2013 | Dec 31, 2012 | $6.50M | Mar 21, 2014 |
| FY2012 | Dec 31, 2011 | $6.12M | Mar 22, 2013 |
| FY2011 | Dec 31, 2010 | $5.79M | Mar 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.16M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.58M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.25M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.84M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $4.68M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.93M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.37M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.05M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $4.30M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.88M | Mar 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $446.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $275.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $100.0K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $410.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($124.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $187.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($10.0K) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $295.0K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $202.0K | Mar 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.0K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($28.0K) | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($37.0K) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $441.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($204.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($31.0K) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($145.0K) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $410.0K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $170.0K | Mar 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $991.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.01M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $973.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $836.0K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $876.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $836.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $811.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $813.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $812.0K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $767.0K | Mar 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $662.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $129.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $321.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($147.0K) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $769.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $331.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $152.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $130.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $468.0K | Mar 20, 2019 |
| FY2016 | Dec 31, 2016 | $196.0K | Mar 29, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $51.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $70.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $65.0K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $141.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $25.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $107.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $32.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $114.0K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $8.0K | Mar 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.70M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.89M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $14.45M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $14.04M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $13.89M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $13.32M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.48M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $13.28M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $13.42M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $13.06M | Mar 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.82M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.33M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $13.76M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $13.41M | Mar 19, 2025 |
| FY2023 | Dec 31, 2021 | $13.19M | Mar 20, 2024 |
| FY2022 | Dec 31, 2020 | $12.77M | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | $12.89M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $12.73M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $12.71M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $12.32M | Mar 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.94M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $11.63M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $11.18M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $10.91M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $10.81M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $10.40M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $10.52M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $10.34M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $10.35M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $10.06M | Mar 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.55M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.95M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $9.87M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $7.65M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $6.71M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.09M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $8.79M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.06M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $963.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $840.0K | Mar 20, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $390.0K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $771.0K | Mar 14, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.48M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 3.45M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 3.43M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 3.43M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 3.40M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 3.40M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 3.40M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 3.40M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 3.40M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | 3.40M | Mar 20, 2018 |